Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group.
Ifrah N, Witz F, Jouet JP, François S, Lamy T, Linassier C, Pignon B, Berthou C, Guyotat D, Cahn JY, Harousseau JL. Ifrah N, et al. Among authors: witz f. Cancer. 1999 Oct 15;86(8):1496-505. doi: 10.1002/(sici)1097-0142(19991015)86:8<1496::aid-cncr16>3.0.co;2-#. Cancer. 1999. PMID: 10526278 Clinical Trial.
A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Witz F, Sadoun A, Perrin MC, Berthou C, Brière J, Cahn JY, Lioure B, Witz B, François S, Desablens B, Pignon B, Le Prisé PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL. Witz F, et al. Among authors: witz b. Blood. 1998 Apr 15;91(8):2722-30. Blood. 1998. PMID: 9531581 Free article. Clinical Trial.
Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.
Milpied N, Gisselbrecht C, Harousseau JL, Sebban C, Witz F, Troussard X, Gratecos N, Michallet M, LeBlond V, Auzanneau G, et al. Milpied N, et al. Among authors: witz f. Cancer. 1990 Aug 15;66(4):627-31. doi: 10.1002/1097-0142(19900815)66:4<627::aid-cncr2820660404>3.0.co;2-0. Cancer. 1990. PMID: 2386891
Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M, Lioure B, Lamy T, Desablens B, Guilhot F, Caillot D, Abgrall JF, Francois S, Briere J, Guyotat D, Casassus P, Audhuy B, Tellier Z, Hurteloup P, Herve P. Harousseau JL, et al. Among authors: witz f. Blood. 1997 Oct 15;90(8):2978-86. Blood. 1997. PMID: 9376578 Free article. Clinical Trial.
Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia.
Pigneux A, Tanguy ML, Michallet M, Jouet JP, Kuentz M, Vernant JP, Milpied N, Ifrah N, Cahn JY, Gratecos N, Reman O, Cure H, Caillot D, Witz F, Pillier-Loriette C, Tron P, Reiffers J; Société Française de Greffe de Moelle. Pigneux A, et al. Among authors: witz f. Br J Haematol. 2002 Jan;116(1):193-201. doi: 10.1046/j.1365-2141.2002.03235.x. Br J Haematol. 2002. PMID: 11841417 Free article.
Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission.
Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation. Gorin NC, et al. Among authors: witz f. Blood. 2010 Oct 28;116(17):3157-62. doi: 10.1182/blood-2009-11-252197. Epub 2010 May 17. Blood. 2010. PMID: 20479285 Free article.
Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group.
Bertoli S, Bories P, Béné MC, Daliphard S, Lioure B, Pigneux A, Vey N, Delaunay J, Leymarie V, Luquet I, Blanchet O, Cornillet-Lefebvre P, Hunault M, Bouscary D, Fegueux N, Guardiola P, Dreyfus F, Harousseau JL, Cahn JY, Ifrah N, Récher C; Groupe Ouest-Est d’Etude des Leucémies Aiguës et Autres Maladies du Sang (GOELAMS). Bertoli S, et al. Haematologica. 2014 Jan;99(1):46-53. doi: 10.3324/haematol.2013.091819. Epub 2013 Aug 23. Haematologica. 2014. PMID: 23975179 Free PMC article. Clinical Trial.
Treatment of acute myelogenous leukaemia in patients aged 50-65: idarubicin is more effective than zorubicin for remission induction and prolonged disease-free survival can be obtained using a unique consolidation course. The Goelam Group.
Pignon B, Witz F, Desablens B, Leprise PY, Francois S, Linassier C, Berthou C, Caillot D, Lioure B, Cahn JY, Casassus P, Sadoun A, Audhuy B, Guyotat D, Briere J, Vilque JP, Baranger L, Polin V, Berthaud P, Hurteloup P, Herve P, Harousseau JL. Pignon B, et al. Among authors: witz f. Br J Haematol. 1996 Aug;94(2):333-41. doi: 10.1046/j.1365-2141.1996.d01-1803.x. Br J Haematol. 1996. PMID: 8759894 Clinical Trial.
89 results